Development of new therapies for childhood sarcoma
José Sánchez Toledo. Vall d’Hebron Institute of Oncology (VHIO)
The project aims to identify the molecules responsible for the growth of rhabdomyosarcoma (RMS), a type of childhood cancer which frequently originates in muscle tissue, in order to develop new therapies that can combat this disease more effectively.
Rhabdomyosarcoma is a solid tumour in which nearly half the patients present an adverse prognosis and for which the development of new complementary therapies could represent an important progress in terms of patient survival and quality of life.
The project will study the oncogenic pathway known as Hedgehog, key for the growth of this kind of tumour, in order to develop new specific therapies.
There are currently no therapies against this specific target, so any inhibition strategies and drugs considered are completely innovative.